Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy

Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy

US Patent 11365236 · Granted Jun 21, 2022

Estimated economic value: $22,909,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method to specifically stimulate survival and expansion of genetically-modified 2025
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use t2025
Polymeric amphoteric surfactant compound2025
Neutralization of human cytokines with membrane-bound anti-cytokine non-signalin2025
Methods for enhancing efficacy of therapeutic immune cells2025
Methods for enhancing efficacy of therapeutic immune cells2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025